ORIC Pharmaceuticals to Showcase Key Oncology Data at ESMO 2026
Event summary
- ORIC Pharmaceuticals will present three posters at ESMO Congress 2026 in Madrid, Spain (Oct. 23-27).
- Enozertinib Phase 1b trial data for first-line EGFR atypical NSCLC to be highlighted.
- Rinzimetostat Phase 3 study design (Himalayas-1) and preclinical mCRPC data presented.
- Full abstracts available Oct. 19, 2026 via ESMO Congress website.
The big picture
ORIC's ESMO presentations come as precision oncology continues to gain traction, with increasing focus on overcoming resistance mechanisms. The company is positioning itself at the intersection of targeted therapies for NSCLC and novel approaches to metastatic castration-resistant prostate cancer (mCRPC). Success in these areas could significantly expand ORIC's market potential beyond current clinical-stage assets.
What we're watching
- Clinical Validation
- Whether enozertinib's Phase 1b data can position it as a viable option for EGFR atypical NSCLC patients.
- Regulatory Pathway
- The pace at which rinzimetostat's Himalayas-1 Phase 3 trial progresses toward potential approval.
- Competitive Positioning
- How ORIC differentiates its PRC2 inhibitor approach in the crowded prostate cancer treatment landscape.
Related topics